Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.1B
118M shares
52-week range
$22.22 – $42.81
59% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
3.3
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
www.indivior.comNo one on the platform currently holds INDV.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 37,141 | $1.1M |
No one on the platform has traded INDV yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 401.5% | — | — | — | ||
| Rev. Growth % | 4.3% | 13.9% | ||||
| Profit Margin % | 16.9% | 5.3% | 5.7% | |||
| Free Cash Flow Margin % | -7.6% | -0.0% | 7.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +0.3% on the P/E track.
At today's price, your expected annual return is +5.0% on the P/E track.
At today's price, your expected annual return is +9.2% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +11.8% | $4.22 | $4.18–$4.25 | 8.1× | 2 |
| 2027 | $1.4B | +5.1% | $4.62 | $4.58–$4.65 | 7.4× | 2 |
| 2028 | $1.5B | +6.4% | $4.84 | $4.32–$5.36 | 7.1× | 2 |
| 2029 | $1.5B | +3.8% | $4.99 | $4.94–$5.01 | 6.9× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $0.87 | $1.15 | +32.3% |
| 2026-04-30 | $0.64 | $0.96 | +50.0% |
| 2026-02-26 | $0.65 | $0.82 | +26.2% |
| 2025-10-30 | $0.38 | $0.72 | +89.5% |
| 2025-07-31 | $0.26 | $0.51 | +96.2% |
| 2025-04-24 | $0.22 | $0.41 | +86.4% |
| 2025-02-20 | $0.32 | $0.32 | +0.0% |
| 2024-10-24 | $0.31 |
| $0.54 |
| +74.2% |
| +0.00% |
| $9.0B |
| — |
| HNGEHinge Health, Inc. | $94.07 | -0.76% | $7.3B | — |
| LNTHLantheus Holdings, Inc. | $100.42 | +0.10% | $6.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
https://www.marketbeat.com/earnings/reports/2026-8-3-indivior-plc-stock-1/ $INDV Indivior Earnings Transcript
View on StockTwits ↗
$ATKR $FERG $SUPN $INDV $BMY PRE-MARKET MOVERS: Currently Higher: - Atkore (ATKR) up 27.9% after entering into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8B - Ferguson (FERG) up 8.2% ahead of its entry into the S&P 500 - Supernus (SUPN) up 14.3% after the company and Indivior entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Indivior (INDV) up 1.2% after Supernus and the company entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Bristol Myers (BMY) up 3.1% after Financial Times reported AstraZeneca (AZN) is in discussions to combine with the company in a deal valued at nearly $400B Currently Lower After Earnings: - Sportradar (SRAD) down 19.2% - Krystal Biotech (KRYS) down 5.6% - TG Therapeutics (TGTX) down 2.7% - Marriott (MAR) down 2.2% Currently Also Lower: - AstraZeneca (AZN) down 7.1% after Financial Times reported the company is in discussions to combine with Bristol Myers Squibb in a deal valued at nearly $400B - Circle Internet (CRCL) down 5.6% after Morgan Stanley downgraded the stock to Underweight with a price target of $38, down from $106
View on StockTwits ↗
$SUPN: Supernus Pharma (+14.3%) and Indivior Pharmaceuticals $INDV to merge; expected to close in Q4 of 2026.
View on StockTwits ↗
$SUPN and $INDV merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility. https://notreload.xyz/xy/supn-indv-merge-to-form-2-2b-cns-leader/
View on StockTwits ↗
$INDV Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $5.10 up 580.00% YoY • Reported revenue of $343M up 13.58% YoY • Indivior raised its full-year 2026 financial guidance, now expecting net revenue of $1,295 million to $1,365 million, total SUBLOCADE net revenue of $1,010 million to $1,050 million, and adjusted EBITDA of $700 million to $740 million.
View on StockTwits ↗
Hugging the line! $INDV tests the 21-EMA as the next move takes shape Indivior ($INDV) finished at $40.54. The stock absorbed recent healthcare sector rotation and continues building a base while holding near its key short-term trend line. This is a classic 21-EMA continuation setup. Bulls need volume confirmation to push price above the current consolidation zone and trigger a possible momentum breakout. If the breakout takes longer, the previous horizontal support area remains the key accumulation zone. The chart is showing patience, not weakness. The next reaction from this level could define the short-term trend. Charts tell the story before headlines do.
View on StockTwits ↗$INDV I made an entry to invest how I can into suboxone From my understanding it will help people get off the gas station heroin which is supposed to be banned soon 🤷♂️ I pray for anyone addicted to drugs
View on StockTwits ↗
$INDV | Barclays Starts Indivior at Overweight with $46 PT on EBITDA Growth and Sublocade Momentum Barclays stays bullish as management execution, cost optimization, and mid-teens Sublocade growth support long-term upside. 🔹 Follow @tenet_research for more analyst insights on other tickers.
View on StockTwits ↗
$INDV Share Price: $37.65 Contract Selected: Nov 20, 2026 $40 Calls Buy Zone: $2.72 – $3.36 Target Zone: $4.73 – $5.78 Potential Upside: 64% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$INDV Outstanding article that hits the mark on INDV's current state. So if you want to refresh your INDV insights or learn about INDV from scratch, this is a must read. https://everyticker.com/quote/INDV/analysis/indivior-s-sublocade-transformation-margin-inflection-meets-patent-protected-growth-nasdaq-indv
View on StockTwits ↗
Indivior PLC shares rose Monday after the company announced a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC. The ASR is part of Indivior’s previously authorized $400 million buyback program and reflects confidence in its long-term strategy, cash flow generation, and disciplined capital allocation. Under the deal, Indivior will make an upfront $175 million payment and expects to receive an initial delivery of 3,717,473 shares. The final number of shares will depend on the volume-weighted average price during the ASR period, minus a discount. Final settlement is expected by the end of June 2026. The company said the ASR will not impact its previously issued financial guidance. The remaining $100 million under the buyback authorization may be used for additional repurchases depending on market conditions. $INDV
View on StockTwits ↗
$INDV (+2.9% pre) Indivior launches $175M accelerated share buyback https://ooc.bz/l/100901
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.